Kelly WK - Search Results

1

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.

Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Martin DT, et al. Among authors: kelly wk. Nanomedicine. 2013 Nov;9(8):1124-34. doi: 10.1016/j.nano.2013.05.017. Epub 2013 Jun 11. Nanomedicine. 2013. PMID: 23764660 Free PMC article.

2

Redefining hormone resistance in prostate cancer.

Hoimes CJ, Kelly WK. Hoimes CJ, et al. Among authors: kelly wk. Ther Adv Med Oncol. 2010 Mar 1;2(2):107-123. doi: 10.1177/1758834009356433. Ther Adv Med Oncol. 2010. PMID: 20543967 Free PMC article.

3

TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.

Hoimes CJ, Kelly WK. Hoimes CJ, et al. Among authors: kelly wk. Update Cancer Ther. 2009;3(4):157-159. doi: 10.1016/j.uct.2009.03.001. Update Cancer Ther. 2009. PMID: 19655026 Free PMC article. No abstract available.

4

Histone deacetylase inhibitors: biology and mechanism of action.

Mehnert JM, Kelly WK. Mehnert JM, et al. Among authors: kelly wk. Cancer J. 2007 Jan-Feb;13(1):23-9. doi: 10.1097/PPO.0b013e31803c72ba. Cancer J. 2007. PMID: 17464243 Review.

5

Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States.

Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Apolo AB, et al. Among authors: kelly wk. Urol Oncol. 2014 Jul;32(5):637-44. doi: 10.1016/j.urolonc.2013.12.012. Epub 2014 May 16. Urol Oncol. 2014. PMID: 24840869 Free PMC article.

6

CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy.

Kelly WK, Marks P, Richon VM. Kelly WK, et al. Clin Cancer Res. 2015 May 15;21(10):2198-200. doi: 10.1158/1078-0432.CCR-14-2556. Clin Cancer Res. 2015. PMID: 25979925

7

Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.

Lee JJ, Kelly WK. Lee JJ, et al. Among authors: kelly wk. Nat Clin Pract Oncol. 2009 Feb;6(2):85-92. doi: 10.1038/ncponc1281. Epub 2008 Dec 2. Nat Clin Pract Oncol. 2009. PMID: 19048010 Review.

8

Histone deacetylase inhibitors: development as cancer therapy.

Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T. Marks PA, et al. Among authors: kelly wk. Novartis Found Symp. 2004;259:269-81; discussion 281-8. Novartis Found Symp. 2004. PMID: 15171260

9

Histone deacetylase inhibitors.

Kelly WK. Kelly WK. Clin Adv Hematol Oncol. 2004 Nov;2(11):722-3. Clin Adv Hematol Oncol. 2004. PMID: 16163258 No abstract available.

10

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.

de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard ES, Hardiman G, Hussain MH, Diehl JA, Drake JM, Kelly WK, Knudsen KE. de Leeuw R, et al. Among authors: kelly wk. Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8. Clin Cancer Res. 2018. PMID: 29739788 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

231 results

Search Page

Filters